v3.26.1
GOODWILL AND INTANGIBLE ASSETS (Tables)
 12 Months Ended
Dec. 31, 2025
Goodwill and Intangible Assets Disclosure [Abstract]  
SCHEDULE OF INTANGIBLE ASSETS WERE DETERMINED TO BE PRODUCT TECHNOLOGIES

Product Candidate  Fair Value 
SCN-102(a)  $23,600,000 
SCN-104(b)   25,000,000 
SCN-106(c)   15,000,000 
SCN-107(d)   12,800,000 
   $76,400,000 

 

  (a) SCN-102 received regulatory approval in March 2025.Product commercialization began in the third quarter of 2025.
  (b) Management expects SCN-104 to achieve regulatory approval in late 2027 or early 2028, with product commercialization projected to begin in 2028.
  (c) Management expects SCN-106 to achieve regulatory approval in 2027 or 2028, with product commercialization projected to begin in 2028.
  (d) Management expects SCN-107 to achieve regulatory approval in 2028 or 2029, with product commercialization projected to begin in 2029.
SCHEDULE OF GOODWILL

 

   (in thousands) 
Balance, December 31, 2024  $21,373 
Impairment charge   (21,373)
Balance, December 31, 2025  $— 
SCHEDULE OF INTANGIBLE ASSETS IMPAIRMENT TEST RESPECTIVE ESTIMATED FAIR VALUE

Asset  Carrying Amount   Fair Value   Impairment Loss 
SCN-104 (DHE Mesylate Injection)  $25,000   $22,339   $(2,661)
SCN-106 (Cathflo Injection – Potential Biosimilar)  $15,000   $13,381   $(1,619)
SCN-107 (Bupivacaine Long-Acting Injection)  $12,800   $12,107   $(693)
Total IPR&D impairment charges         $(4,973)
SCHEDULE OF INTANGIBLE ASSETS

Asset  Dec 31, 2025   Dec 31, 2024 
SCN-102 – finite-lived (net of $454 amortization)  $23,146   $23,600 
SCN-104 – indefinite-lived IPR&D  $22,339   $25,000 
SCN-106 – indefinite-lived IPR&D  $13,381   $15,000 
SCN-107 – indefinite-lived IPR&D  $12,107   $12,800 
Total intangible assets, net  $70,973   $76,400